Delivery Order SPE2DB25D3012-SPE2DB25FWZAK
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,265.40 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 15, 2025. The contract represents a firm fixed price, non-set-aside delivery order executed on September 12, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This award is a child contract under AmerisourceBergen's substantial $999,999,999...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,054.35. This is a firm fixed price, non-set-aside delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,170.50 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This firm fixed price, competitively awarded contract was issued on July 25, 2025, with an ultimate completion date of July 28, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in Conshohocken, PA. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $1,747.44 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 29, 2025. This non-competitive delivery order represents a firm fixed price transaction and is classified as a child contract under AmerisourceBergen's larger contract vehicle with DLA. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,027.62 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency awarded a $3,734.26 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitive delivery order, which is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), carries a firm fixed price structure and is scheduled for completion by August 15, 2025. The product will be delivered to the company's facilities in...
- The Defense Logistics Agency (DLA) awarded a $4,702.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The award, issued on August 11, 2025, with completion targeted for August 12, 2025, represents a single delivery order under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical. This contract was competitively awarded with no set-aside designation and will be performed at the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $1,405.80 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on August 20, 2025, with a completion date of August 21, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FWZAKDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,661.10 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which is valued at $999.999 billion through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing critical medical procurement support to federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The company's federal contract portfolio demonstrates extensive capability in supplying a broad spectrum of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This specific delivery order for NovoLog insulin aligns with the company's established role as a primary vendor for diabetes management medications and other critical pharmaceuticals supporting military medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 8/5/25 |